Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECCE327 versus oral standard-of-care antibiotics for diabetic foot infection (Part B)
ACTRN12626001202358Phase 3Not yet recruiting
- Sponsor
- Recce Pharmaceuticals Ltd
- Start
- Oct 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in diabetic foot infection (DFI) comparing RECCE327 topical gel with Physician-selected oral antibiotic standard of care (2 arms). Primary endpoint: Clinical response of diabetic foot infection. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
RECCE 327
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on ACTRN12626001202358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001202358.